These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1466952)

  • 1. Phase I/II studies of the toxicity and immunogenicity of recombinant gp160 and p24 vaccines in HIV-infected individuals.
    Zunich KM; Lane HC; Davey RT; Falloon J; Polis M; Kovacs JA; Masur H
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1335. PubMed ID: 1466952
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical trials of AIDS vaccines in seronegative volunteers: vectors and combinations.
    Graham BS
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1327-8. PubMed ID: 1466951
    [No Abstract]   [Full Text] [Related]  

  • 3. Vaccine therapy using rgp 160 in early HIV infection.
    Redfield R; Birx D; Ketter N; Polonis V; Johnson S; Davis C; Smith G; Oster C; Burke D
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1333. PubMed ID: 1361350
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunization with recombinant gp160 prolongs the survival of HIV-1 transgenic mice.
    Shirai A; Klinman DM
    AIDS Res Hum Retroviruses; 1993 Oct; 9(10):979-83. PubMed ID: 8280480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. Clin Exp Immun 1994;98:178-84.
    DePalma L
    Pediatr AIDS HIV Infect; 1995 Apr; 6(2):97-8. PubMed ID: 11361387
    [No Abstract]   [Full Text] [Related]  

  • 6. HIV experimental vaccines based on the iscom technology using envelope and GAG gene products.
    Akerblom L; Nara P; Dunlop N; Putney S; Morein B
    Biotechnol Ther; 1993; 4(3-4):145-61. PubMed ID: 8292967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with gp160 in HIV.
    Oyaizu N; Chirmule N; Pahwa S
    N Engl J Med; 1992 Jan; 326(5):347; author reply 348. PubMed ID: 1728747
    [No Abstract]   [Full Text] [Related]  

  • 8. AIDS vaccine boosts immunity in HIV patients.
    RN; 1991 Oct; 54(10):103. PubMed ID: 1925340
    [No Abstract]   [Full Text] [Related]  

  • 9. Current progress in HIV vaccines.
    Westblom TU; Belshe RB; Gorse GJ
    Mo Med; 1991 Nov; 88(11):762-5. PubMed ID: 1805131
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunization of HIV-infected patients with rgp160: modulation of anti-rgp120 antibody spectrotype.
    Biselli R; Loomis LD; Del Bono V; Burke DS; Redfield RR; Birx DL
    J Acquir Immune Defic Syndr (1988); 1994 Oct; 7(10):1016-24. PubMed ID: 8083819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of gp160 vaccinees in the hu-PBL-SCID mouse model.
    Mosier DE; Gulizia RJ; MacIsaac P; Mathieson BJ; Smith G; Hu SL; Corey L; Greenberg P
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1387. PubMed ID: 1466962
    [No Abstract]   [Full Text] [Related]  

  • 12. Vaccination with gp160 in HIV.
    Stanberry LR; Bernstein DI; Myers MG
    N Engl J Med; 1992 Jan; 326(5):347-8. PubMed ID: 1728748
    [No Abstract]   [Full Text] [Related]  

  • 13. Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine.
    Kundu SK; Katzenstein D; Moses LE; Merigan TC
    Proc Natl Acad Sci U S A; 1992 Dec; 89(23):11204-8. PubMed ID: 1360665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. USA: therapeutic AIDS vaccine trial debated.
    Rowe PM
    Lancet; 1992 Nov; 340(8829):1216. PubMed ID: 1359275
    [No Abstract]   [Full Text] [Related]  

  • 15. Trial results thwart HIV-vaccine hopes.
    McCarthy M
    Lancet; 1996 Apr; 347(9009):1173. PubMed ID: 8609757
    [No Abstract]   [Full Text] [Related]  

  • 16. HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques.
    Abimiku AG; Franchini G; Tartaglia J; Aldrich K; Myagkikh M; Markham PD; Chong P; Klein M; Kieny MP; Paoletti E
    Nat Med; 1995 Apr; 1(4):321-9. PubMed ID: 7585061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a vaccinia-derived recombinant HIV-1 gp160 candidate vaccine and its immunogenicity in chimpanzees.
    Barrett N; Eder G; Dorner F
    Biotechnol Ther; 1991; 2(1-2):91-106. PubMed ID: 1845126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
    Dis Markers; 1991; 9(1):51. PubMed ID: 1742945
    [No Abstract]   [Full Text] [Related]  

  • 19. Properties of an HIV 'vaccine'.
    Wahren B; Sandström E; Wigzell H
    Nature; 1993 Apr; 362(6420):505; author reply 505-6. PubMed ID: 8464491
    [No Abstract]   [Full Text] [Related]  

  • 20. The prospects for AIDS vaccines.
    Koff WC
    Hosp Pract (Off Ed); 1991 Apr; 26(4):99-106. PubMed ID: 2010483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.